Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–13 of 13 results
Advanced filters: Author: Lelia Delamarre Clear advanced filters

  • A combination of genome-wide exome and transcriptome analysis, mass spectrometry and computational structural modelling are used here to identify immunogenic neo-antigens in two mouse tumour cancer cell lines; mice vaccinated with predicted immunogenic peptides yielded therapeutically useful cytotoxic T-lymphocyte responses.

    • Mahesh Yadav
    • Suchit Jhunjhunwala
    • Lélia Delamarre
    Research
    Nature
    Volume: 515, P: 572-576

  • Immunotherapy treatment harnesses CD8 T cells of the immune system to kill tumour cells. The finding that CD4 helper T cells contribute to the success of this treatment in mice might offer a way to improve clinical outcomes.

    • Jonathan L. Linehan
    • Lélia Delamarre
    News & Views
    Nature
    Volume: 574, P: 639-640

  • In this phase 1 trial, patients with locally advanced or metastatic solid tumors were treated with the individualized mRNA neoantigen-specific immunotherapy (iNeST) autogene cevumeran alone or in combination with the anti-PD-L1 agent atezolizumab, showing long-lasting neoantigen-specific immune responses and preliminary clinical activity, supporting further development of this therapeutic approach.

    • Juanita Lopez
    • Thomas Powles
    • D. Ross Camidge
    ResearchOpen Access
    Nature Medicine
    Volume: 31, P: 152-164

  • Computational methods are used to predict which peptides or antigens are able to bind to MHC in order to activate T cell receptors in neoantigen-directed immunotherapies. Here the authors present an accurate transformer-based method to consider not only the peptide and MHC but also the source antigenic protein to predict peptides which bind to MHC molecules.

    • William John Thrift
    • Nicolas W. Lounsbury
    • Suchit Jhunjhunwala
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-16

  • This Perspective considers present and historical paradigms of therapeutic cancer vaccines and describes a conceptual framework, termed Vax-Innate, to simultaneously generate robust tumour-specific T cell responses and remodel the suppressive tumour microenvironment (TME). The authors detail how this strategy could be achieved through systemic vaccination and by using immune modulators to improve dendritic cell and macrophage function in the TME.

    • Faezzah Baharom
    • Dalton Hermans
    • Robert A. Seder
    Reviews
    Nature Reviews Immunology
    Volume: 25, P: 195-211

  • RNA vaccines have been associated with high reactogenicity. Mellman and colleagues demonstrate that lipid-formulated RNA vaccines trigger IL-1 production and inflammation in humans but this pathway is dampened in mice.

    • Siri Tahtinen
    • Ann-Jay Tong
    • Ira Mellman
    Research
    Nature Immunology
    Volume: 23, P: 532-542

  • Skin tumour array by microporation (STAMP) captures the dynamic relationships of spatial, cellular and molecular components of tumour rejection and has the potential to translate therapeutic concepts into successful clinical strategies.

    • Guadalupe Ortiz-Muñoz
    • Markus Brown
    • Christine Moussion
    ResearchOpen Access
    Nature
    Volume: 618, P: 827-833

  • Large-scale single-cell sequencing of RNA and T cell receptors in samples from patients with cancer shows clonotypic expansion of effector-like T cells not only in tumour tissue but also in normal adjacent tissues and peripheral blood, which associates with clinical response to cancer immunotherapy.

    • Thomas D. Wu
    • Shravan Madireddi
    • Jane L. Grogan
    Research
    Nature
    Volume: 579, P: 274-278

  • Immune checkpoint inhibition does not benefit all patients. This Review discusses how antigen presentation, which is crucial for the success of this therapy, may be disrupted in tumours and dendritic cells of patients, and how tumours may further evade natural killer cell recognition.

    • Suchit Jhunjhunwala
    • Christian Hammer
    • Lélia Delamarre
    Reviews
    Nature Reviews Cancer
    Volume: 21, P: 298-312

  • The endo-lysosomal transporters SLC15A3 and SLC15A4 provide a portal of entry for extracellular bacterial products that activate the cytoplasmic sensor NOD2; these results establish the importance of endosomes as signalling platforms specialized for triggering innate immune responses.

    • Norihiro Nakamura
    • Jennie R. Lill
    • Ira Mellman
    Research
    Nature
    Volume: 509, P: 240-244